MACK Merrimack Pharmaceuticals Inc.

-0.02  -0%
Previous Close 6.57
Open 6.63
Price To Book 2.18
Market Cap 87,441,328
Shares 13,349,821
Volume 13,445
Short Ratio
Av. Daily Volume 55,581

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial termination announced November 7, 2018.
HER2 negative metastatic breast cancer
Phase 2 data released June 25, 2018 - endpoints not met.
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
Cancer - second line pancreatic
Phase 2 trial discontinued due to futility - noted October 19, 2018.
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
Cancer - front line pancreatic
Announced April 4, 2019 discontinuation of development.
Solid tumors
Poster at ASCO June 2018.
Solid tumors

Latest News

  1. Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019
  2. Merrimack Declares $20 Million Special Dividend
  3. The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering
  4. Merrimack axes remaining staff, execs after selling assets to New York startup
  5. Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend
  6. Merrimack Reports First Quarter 2019 Financial Results
  7. COMM 2014-UBS2 Mortgage Trust -- Moody's affirms ten classes of COMM 2014-UBS2
  8. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
  9. Merrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation
  10. The Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather Upset
  11. The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership
  12. Merrimack shelves another cancer drug, plans more layoffs
  13. Merrimack Discontinues Development of MM-310
  14. Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
  15. Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results
  16. New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
  17. Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?